Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Overview
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Companies Involved in Therapeutics Development
Ctcbio Inc
Sobrera Pharma AB
Sopharma AD
Suven Life Sciences Ltd
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Drug Profiles
(varenicline tartrate + bupropion hydrochloride) SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDFF-0318 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cytisinicline - Drug Profile
Product Description
Mechanism Of Action
History of Events
ropanicant [INN] - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize CHRNB2 and CHR4 for Psychiatric Disorders - Drug Profile
Product Description
Mechanism Of Action
varenicline tartrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Dormant Products
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Discontinued Products
Neurol Acetylcholine Receptor Subunit Alpha 4 (CHR4) - Product Development Milestones
Featured News & Press Releases
Apr 27, 2022: Achieve Life Sciences announces successful, statistically significant smoking cessation results in phase 3 ORCA-2 clinical trial of cytisinicline in adult smokers
Jan 25, 2022: Achieve Life Sciences announces initiation of the phase 3 ORCA-3 clinical trial evaluating cytisinicline for smoking cessation
Jan 04, 2022: Achieve Life Sciences announces completion of last subject, last follow-up visit in phase 3 ORCA-2 trial of cytisinicline for smoking cessation
Dec 22, 2021: Achieve Life Sciences announces $25 million loan facility from Silicon Valley Bank to fund cytisinicline smoking cessation clinical development
Nov 22, 2021: Achieve Life Sciences announces phase 3 ORCA-2 trial of cytisinicline in smoking cessation clears fil review by Data Safety Monitoring Committee (DSMC)
Nov 02, 2021: Achieve Life Sciences announces FDA acceptance of IND application for Cytisinicline’s second planned indication for nicotine E-cigarette cessation
Oct 14, 2021: Class 2 Medicines Recall: Pfizer Ltd, Champix (all strengths) film-coated tablets
Sep 20, 2021: Health Cada approves COVID-19 vaccine brand me Comirty
Sep 16, 2021: Pfizer expands voluntary tionwide recall to include all lots of CHANTIX (varenicline) tablets due to N-Nitroso Varenicline Content
Sep 14, 2021: Achieve Life Sciences announces presentation of Cytisinicline data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
Aug 13, 2021: Pfizer expands voluntary tionwide recall to include four additiol lots of CHANTIX (varenicline) tablets due to NNitroso Varenicline content
Aug 13, 2021: Achieve Life Sciences announces expansion of Cytisinicline clinical operations team and granting of inducement awards
Aug 11, 2021: Achieve announces two patents granted by USPTO for novel Cytisinicline dosing and administration regimen
Aug 05, 2021: Therapeutic Goods Administration provides update on Varenicline
Jul 22, 2021: Achieve Life Sciences awarded grant from the tiol Institutes of Health (NIH) for the evaluation of cytisinicline in cessation of nicotine e-cigarette use
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Ctcbio Inc, 2022
Pipeline by Sobrera Pharma AB, 2022
Pipeline by Sopharma AD, 2022
Pipeline by Suven Life Sciences Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022